TCI Wealth Advisors’s Marker Therapeutics MRKR Stock Holding History

TCI Wealth Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10	Closed	-$8	–	1435
2023 Q1	$8	Hold	10	–	–	﹤0.01%	2503
2022 Q4	$27	Sell	10 -10	-50%	-$35	﹤0.01%	2456
2022 Q3	$0	Hold	20	–	–	﹤0.01%	2468
2022 Q2	$0	Hold	20	–	–	﹤0.01%	2434
2022 Q1	$0	Hold	20	–	–	﹤0.01%	2366
2021 Q4	$0	Hold	20	–	–	﹤0.01%	2442
2021 Q3	$0	Hold	20	–	–	﹤0.01%	2500
2021 Q2	$1K	Sell	20 -50	-71%	-$1.32K	﹤0.01%	2226
2021 Q1	$2K	Buy	70 +20	+40%	+$458	﹤0.01%	1811
2020 Q4	$1K	Sell	50 -70	-58%	-$1.09K	﹤0.01%	1411
2020 Q3	$2K	Hold	120	–	–	﹤0.01%	1136
2020 Q2	$2K	Sell	120 -150	-56%	-$3.28K	﹤0.01%	1083
2020 Q1	$5K	Sell	270 -80	-23%	-$2.04K	﹤0.01%	716
2019 Q4	$10K	Buy	350 +70	+25%	+$2.55K	﹤0.01%	705
2019 Q3	$14K	Buy	280 +70	+33%	+$4.14K	0.01%	559
2019 Q2	$17K	Buy	210 +90	+75%	+$5.35K	0.01%	504
2019 Q1	$8K	Buy	+120	New	+$7.01K	﹤0.01%	676

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

MAA

Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCI Wealth Advisors's MRKR Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Marker Therapeutics (MRKR) in Q2 2023, closing a stake of 10 shares — an estimated $8 sold.

TCI Wealth Advisors first reported a position in MRKR in Q1 2019 and held it in 17 quarters. The position peaked at $17K in Q2 2019. 29 funds tracked by Wall St. Rank hold MRKR as of Q2 2023.

TCI Wealth Advisors reported no remaining Marker Therapeutics position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 10 Marker Therapeutics shares in Q2 2023, an estimated $8.
TCI Wealth Advisors first reported a position in Marker Therapeutics in Q1 2019 and held it in 17 quarters.
TCI Wealth Advisors's Marker Therapeutics position peaked at $17K in Q2 2019.
29 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.